EHA 2023 | Defining the optimal duration of treatment with daraCyBorD & dara maintenance in AL amyloidosis
Paolo Milani, MD, PhD, Amyloidosis Research and Treatment Center, Pavia, Italy, sheds light on the current and future role of daratumumab in the treatment of systemic light chain (AL) amyloidosis. Dr Milani explains that now that daratumumab has moved to the frontline setting following the results of ANDROMEDA (NCT03201965), it is important to define the optimal duration of treatment with daratumumab, cyclophosphamide, bortezomib, and dexamethasone (daraCyBorD) as well as daratumumab maintenance. It is also important to clarify the role of autologous stem cell transplantation (autoSCT) in patients who have deep responses with daraCyBorD. This interview took place at the 28th Congress of the European Hematology Association (EHA) 2023 in Frankfurt, Germany.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
